Research for biomarkers to predict the effectiveness of denosumab in metastatic bone tumors

Research for biomarkers to predict the effectiveness of denosumab in metastatic bone tumors - Research for biomarkers to predict the effectiveness of denosumab in metastatic bone tumors

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019700

Enrollment

Registered

2015-11-09

Start date

2013-02-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with bone metastases newly treated by denosumab

Interventions

CT 3 times, bone scintigraphy 3 times, laboratory examination 4 times

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with bone metastases newly treated by denosumab

Exclusion criteria

Exclusion criteria: Fracture, No consent, Contraindication for denosumab

Design outcomes

Primary

Measure	Time frame
Therapeutic effects of CT and bone scintigraphy (3 and 6 months after treatments)	—

Secondary

Measure	Time frame
Value and change of biomarkers, Pain score, Analgesic score, Side effect, PS	—

Countries

Japan

Contacts

Public ContactHiroshi Urakawa

Nagoya University Graduate School and School of Medicine Department of Orthopaedic Surgery

urakawa@med.nagoya-u.ac.jp052-744-1908

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026